Research Article
The Potential Prognostic Value of Dual-Imaging PET Parameters Based on 18F-FDG and 18F-OC for Neuroendocrine Neoplasms
Table 3
Risk factors from univariate analysis and multivariate analysis in predicting PFS.
| | Variables | Univariate analysis | Multivariate analysis | | HR | 95% CI | | HR | 95% CI | |
| | Age (≤45.5 vs >45.5, years) | 0.5256 | 0.256-1.080 | 0.034 | / | / | 0.070 | | Gender (male vs female) | 1.181 | 0.632-2.209 | 0.602 | / | / | / | | Time since diagnosis | 1.768 | 0.851-3.674 | 0.127 | | | | | WHO 2010 grade | 1.386 | 0.939-2.047 | 0.101 | / | / | / | | Sites of metastases | | | | | | | | Liver metastases | 0.560 | 0.297-1.058 | 0.074 | / | / | / | | Lymph node metastases | 0.822 | 0.449-1.506 | 0.526 | / | / | / | | Bone metastases | 0.524 | 0.282-0.972 | 0.04 | / | / | 0.452 | | Lung metastases | 1.003 | 0.423-2.376 | 0.995 | / | / | / | | 18F-OC parameters | | | | | | | | SUVmax (≤163.18 vs >163.18) | 0.884 | 0.492-1.590 | 0.675 | / | / | / | | SSTR-derived TV (≤174.16 mL vs >174.16 mL) | 1.666 | 0.833-3.333 | 0.095 | / | / | / | | SRE (≤20300.3 vs >20300.3) | 2.403 | 0.703-8.208 | 0.034 | 2.511 | 1.047-6.022 | 0.039 | | 18F-FDG parameters | | | | | | | | SUVmax (≤38.93 vs >38.93) | 1.268 | 0.641-2.507 | 0.456 | / | / | / | | MTV (≤1.15 mL vs >1.15 mL) | 2.703 | 1.130-6.466 | 0.025 | / | / | 0.506 | | TLG (≤45.54 vs >45.54) | 2.127 | 1.164-3.885 | 0.026 | / | / | 0.433 | | NETPET grade | 1.849 | 1.144-2.990 | 0.012 | 1.917 | 1.159-3.170 | 0.011 | | CgA (+ vs -) | 0.890 | 0.427-1.854 | 0.756 | / | / | / | | CEA (+ vs -) | 0.534 | 0.234-1.216 | 0.135 | / | / | / | | NSE (+ vs -) | 0.862 | 0.361-2.058 | 0.738 | / | / | / |
|
|
SSTR-derived TV: somatostatin receptor-derived tumor volume; SRE: somatostatin receptor expression; MTV: metabolic tumor volume; TLG: total lesion glycolysis; CgA: ChromograninA; CEA: Carcinoembryonic antigen; NSE: Neuron-specific enolase.
|
